other material
confidence high
sentiment negative
materiality 0.65
ZyVersa reports Q3 2022 net loss of $3.7M, R&D spend up 473% YoY
ZyVersa Therapeutics, Inc.
- Net loss of $3.693M for Q3 2022 vs $1.879M in Q3 2021; nine-month loss $9.445M.
- R&D expenses surged to $2.334M in Q3 2022 from $0.407M, driven by $1.928M in IC100 drug manufacturing.
- Cash used in operations improved to $1.078M for nine months 2022 from $4.460M in 2021.
- Financing provided $1.353M via preferred stock private placement; no revenue disclosed.